Physician profile
Rosy Joseph
NPI 1497774350
$5,225.87
in general payments reported to CMS, 2019-2025
28 companies · $1,233 in 2025
The $1,233 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $188 · 2021: $467 · 2022: $622 · 2023: $712 · 2024: $1,411 · 2025: $1,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,265 · Education: $90.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,264.92 |
| Education | $90.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $863.77 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $632.03 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $371.13 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $363.00 | 2022-2025 | |
| Vifor Pharma, INC. | $328.62 | 2019-2024 | Veltassa, Korsuva |
| Novo Nordisk INC | $318.20 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $307.94 | 2023-2025 | |
| Travere Therapeutics, INC. | $231.46 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $231.42 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $224.33 | 2022-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $209.95 | 2020-2024 | Acthar |
| Horizon Therapeutics Plc | $184.88 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $146.25 | 2019-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $141.34 | 2023-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $137.62 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $109.10 | 2019 | |
| Medtronic, INC. | $84.42 | 2024 | Ellipsys Vascular Access System |
| Opko Pharmaceuticals, LLC | $67.90 | 2023-2025 | Rayaldee |
| Lilly USA, LLC | $61.52 | 2024-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $41.74 | 2021-2023 | Benlysta |
| Renalytix Ai, INC. | $36.30 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Alexion Pharmaceuticals, INC. | $31.96 | 2023 | Ultomiris |
| Mallinckrodt Enterprises LLC | $28.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.30 | 2025 | Relistor |
| Genzyme Corporation | $14.94 | 2019 | |
| Eisai INC. | $14.80 | 2019 | |
| Amarin Pharma, INC. | $13.57 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $12.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosy Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.